| Nov 20 |
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
|
| Nov 19 |
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
|
| Nov 7 |
Relay Therapeutics to Participate in Upcoming Investor Conferences
|
| Nov 6 |
Relay Therapeutics GAAP EPS of -$0.63 beats by $0.14, revenue of $0M misses by $0.08M
|
| Nov 6 |
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
|
| Oct 30 |
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
|
| Oct 28 |
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses
|
| Sep 17 |
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?
|
| Sep 16 |
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
|
| Sep 16 |
Relay up 5% as Street applauds breast cancer candidate data
|
